San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
89bio, Inc announced the appointment of Teresa Perney, PhD as Chief Regulatory and Quality Officer, effective today. Dr Perney brings extensive expertise in regulatory affairs, product development, and quality assurance to the company.
Who to call at 89bio, and when
A new leader at 89bio brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day 89bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at 89bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at 89bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
89bio
Location
San Francisco, California, United States
About
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment 89bio changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma